전체상품검색ALS Awareness Month in 2025: an overview of the possibilities of cell …
페이지 정보
작성자 Marcy 댓글 0건 조회 4회 작성일 25-06-04 07:01본문
January 30, 2025 - The Independent Committee for Control of Data (IDMC) gave uniqure a "emerald light" to begin patient registration in the second group of clinical trials of phase 1-2 episod1 (nct06100276), in the process which AMT-162, a vector-based gene therapy based of the adeno-associated virus (AAV), https://TherapyStemCellFrance.com/ for the treatment of ALS caused by mutations in superoxide dismutase 1 (sod1-als), is being evaluated.
- 이전글Think Your High Stakes Is Safe? 6 Ways You Can Lose It Today 25.06.04
- 다음글The Hidden Gem Of Poker Cash Games 25.06.04
댓글목록
등록된 댓글이 없습니다.
